The DOI matches its Crossref record.
Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal Cancer Cells
Abstract
Purpose: Multiple studies have indicated that cyclooxygenase-2 (COX-2) inhibitors may prevent colon cancer, which is one of the leading causes of cancer death in the western world. Recent studies, however, showed that their long-term use may be limited due to cardiovascular toxicity. This study aims to investigate whether curcumin potentiates the growth inhibitory effect of celecoxib, a specific COX-2 inhibitor, in human colon cancer cells. Experimental Design: HT-29 and IEC-18-K-ras (expressing high levels of COX-2), Caco-2 (expressing low level of COX-2), and SW-480 (no expression of COX-2) cell lines were exposed to different concentrations of celecoxib (0-50 μmol/L), curcumin (0-20 μmol/L), and their combination. COX-2 activity was assessed by measuring prostaglandin E2 production by enzyme-linked immunoassay. COX-2 mRNA levels were assessed by reverse transcription-PCR. Results: Exposure to curcumin (10-15 μmol/L) and physiologic doses of celecoxib (5 μmol/L) resulted in a synergistic inhibitory effect on cell growth. Growth inhibition was associated with inhibition of proliferation and induction of apoptosis. Curcumin augmented celecoxib inhibition of prostaglandin E2 synthesis. The drugs synergistically down-regulated COX-2 mRNA expression. Western blot analysis showed that the level of COX-1 was not altered by treatment with celecoxib, curcumin, or their combination. Conclusions: Curcumin potentiates the growth inhibitory effect of celecoxib by shifting the dose-response curve to the left. The synergistic growth inhibitory effect was mediated through a mechanism that probably involves inhibition of the COX-2 pathway and may involve other non–COX-2 pathways. This synergistic effect is clinically important because it can be achieved in the serum of patients receiving standard anti-inflammatory or antineoplastic dosages of celecoxib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
CURCUMIN: THE INDIAN SOLID GOLD
Aggarwal, B. B., Sundaram, C., Malani, N., & Ichikawa, H. (2007) · ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY · doi:10.1007/978-0-387-46401-5_1 · Cited by 1,647
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., & Maitra, A. (2007) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-5-3 · Cited by 1,090
Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials
Strimpakos, A. S., & Sharma, R. A. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1769 · Cited by 645
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Metadata
- Authors
- Lev-Ari, S., Strier, L., Kazanov, D., Madar-Shapiro, L., Dvory-Sobol, H., Pinchuk, I., Marian, B., Lichtenberg, D., & Arber, N.
- Venue
- Clinical Cancer Research
- Published
- 2005-09-15
- Volume
- 11
- Issue
- 18
- Pages
- 6738-6744
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2125943630
- Cited by
- 221
- References
- 0
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal Cancer Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-0171
- The paper
- Lev-Ari, S., Strier, L., Kazanov, D., Madar-Shapiro, L., Dvory-Sobol, H., Pinchuk, I., Marian, B., Lichtenberg, D., & Arber, N. (2005). Celecoxib and Curcumin Synergistically Inhibit the Growth of Colorectal Cancer Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-0171
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.